Yposkesi Acquisition Fuels SK's Global Push Into Biologics Manufacturing

Adds Gene, Cell Therapy Capabilities

South Korean conglomerate SK Group continues its cross-border acquisitions of contract manufacturers, this time of French biologics specialist Yposkesi, marking a new push into the gene and cell therapy sector as it looks to become a global leader in the production of both innovative chemical drugs and biologics.

SK-Yposkesi
Aslam Malik, CEO, SK Pharmteco (L) And Dong-Hyun Jang, CEO, SK Inc. • Source: SK Inc.

SK Inc., an investment holding company of South Korea's SK Group, has become the biggest shareholder of Yposkesi, a French contract manufacturing organization (CMO) focusing on gene therapies. It is SK's third acquisition of this type of operation as it looks to build out its international activities in what it sees as a growth area.

Through the deal, to be routed through SK's SK Pharmteco subsidiary, a US-based holding company for its contract manufacturing businesses,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.